{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-069624","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.670309+00:00","generated_at":"2026-06-18T03:00:33.300754+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Larimar reports Q4 2022 net loss $9.4M; Phase 2 CTI-1601 trial on track with data 2H 2023","bullets":["Net loss of $9.4M ($0.21 per share) in Q4 2022 vs $9.1M ($0.50 per share) in Q4 2021; FY 2022 net loss $35.4M.","Cash, cash equivalents and marketable securities of $118.4M at Dec 31, 2022, projected runway into 2H 2024.","Phase 2 trial first cohort (25 mg) of CTI-1601 fully enrolled; update on next steps expected Q2 2023 after FDA/IDMC review.","Top-line safety, PK and PD (frataxin level) data from both cohorts expected in 2H 2023; Feb 2023 appointed Dr. Gopi Shankar as CDO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-069624","json":"https://secwatch.observer/filing/0001193125-23-069624.json","markdown":"https://secwatch.observer/filing/0001193125-23-069624.md","text":"https://secwatch.observer/filing/0001193125-23-069624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/d475352d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:00:33.300754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a702e1bf6bed15dd8119b8e3bd52ba928822582e","claim":"Larimar Therapeutics, Inc. reported the year ended December 31, 2022 results: net income net loss of $35.4 million, EPS $1.37 per share.","evidence_excerpt":"For the full year 2022, the Company reported a net loss of $35.4 million, or $1.37 per share, compared to a net loss of $50.6 million, or $2.95 per share for the same period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"net loss of $35.4 million"},{"label":"EPS","value":"$1.37 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eef938fac2a8337afa14608c636d60d9c0101336","claim":"Larimar Therapeutics, Inc. reported fourth quarter of 2022 results: net income net loss of $9.4 million, EPS $0.21 per share.","evidence_excerpt":"The Company reported a net loss for the fourth quarter of 2022 of $9.4 million, or $0.21 per share, compared to a net loss of $9.1 million, or $0.50 per share, for the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312523069624/0001193125-23-069624-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2022"},{"label":"Net income","value":"net loss of $9.4 million"},{"label":"EPS","value":"$0.21 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}